Young blood transfusion: Difference between revisions
medium source fails RS much less MEDRS |
|||
| Line 7: | Line 7: | ||
Ambrosia, a company founded by Jesse Karmazin, sells what it calls "young blood transfusions" for $8,000 under the guise of running a [[clinical trial]]. Karmazin claims in an interview with ''[[New Scientist]]'' that "Whatever is in young blood is causing changes that appear to make the ageing process reverse".<ref name="NS17" /><ref name="MIT17" /> There is no evidence that these transfusions do anything, and people who undergo them are at risk of complications, including infections.<ref name="NS17" /><ref name="MIT17" /> |
Ambrosia, a company founded by Jesse Karmazin, sells what it calls "young blood transfusions" for $8,000 under the guise of running a [[clinical trial]]. Karmazin claims in an interview with ''[[New Scientist]]'' that "Whatever is in young blood is causing changes that appear to make the ageing process reverse".<ref name="NS17" /><ref name="MIT17" /> There is no evidence that these transfusions do anything, and people who undergo them are at risk of complications, including infections.<ref name="NS17" /><ref name="MIT17" /> |
||
Billionaire [[Peter Thiel]] is a prominent investor in Ambrosia and has interests in other potentially [[Life extension|life-extending]] treatments, though he specifically states that he has not tried parabiosis. Jeff Bercovici wrote for ''[[Inc. (magazine)|Inc.]]'' that "life-extension science is a popular obsession" in [[silicon valley]] and that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood".<ref name="Inc" /> The practice was referenced in a 2017 episode of comedy series ''[[Silicon Valley]]'' in which the boss of a technology company uses transfusions from a "blood boy" in an attempt to stay young and live longer.<ref name="HR17" /> |
|||
News media have widely reported such practices using [[hyperbole]], likening the procedure to the [[Fountain of Youth]] and the [[elixir of life]].<ref name="SA17 |
News media have widely reported such practices using [[hyperbole]], likening the procedure to the [[Fountain of Youth]] and the [[elixir of life]].<ref name="SA17" /> Others have related it to stories of [[vampire]]s.<ref name="Eco17" /><ref name="CBC18" /> |
||
==See also== |
==See also== |
||
| Line 84: | Line 84: | ||
</ref> |
</ref> |
||
<ref name="Med17"> |
|||
{{cite news |
|||
|url=https://medium.com/immortal-coin/young-blood-transfusions-the-elixir-of-youth-558de42d2086 |
|||
|title=Young Blood Transfusions - The Elixir Of Youth? |
|||
|publisher=Medium |
|||
|date=1 November 2017 |
|||
|accessdate=6 May 2018 |
|||
}} |
|||
</ref> |
|||
<ref name="MIT17"> |
<ref name="MIT17"> |
||
Revision as of 20:39, 22 May 2018
 | This article needs more reliable medical references for verification or relies too heavily on primary sources. (May 2018) |  |
 | This article may present fringe theories, without giving appropriate weight to the mainstream view and explaining the responses to the fringe theories. (May 2018) |
| This article contains content that is written like an advertisement. (May 2018) |
Young blood transfusion refers to the transferral of blood from a young source into an older animal with the intention of having a medicinal effect beyond that of a normal blood transfusion. Tests in mice have returned favourable results and clinical trials involving humans are ongoing. The practice is seen as being a "current trend" in regenerative medicine and life extension while news reports relate it to various tales of immortality.
Society and culture
Ambrosia, a company founded by Jesse Karmazin, sells what it calls "young blood transfusions" for $8,000 under the guise of running a clinical trial. Karmazin claims in an interview with New Scientist that "Whatever is in young blood is causing changes that appear to make the ageing process reverse".[1][2] There is no evidence that these transfusions do anything, and people who undergo them are at risk of complications, including infections.[1][2]
Billionaire Peter Thiel is a prominent investor in Ambrosia and has interests in other potentially life-extending treatments, though he specifically states that he has not tried parabiosis. Jeff Bercovici wrote for Inc. that "life-extension science is a popular obsession" in silicon valley and that there are rumours of wealthy technology bosses "spending tens of thousands of dollars for the procedures and young-person-blood".[3] The practice was referenced in a 2017 episode of comedy series Silicon Valley in which the boss of a technology company uses transfusions from a "blood boy" in an attempt to stay young and live longer.[4]
News media have widely reported such practices using hyperbole, likening the procedure to the Fountain of Youth and the elixir of life.[5] Others have related it to stories of vampires.[6][7]
See also
References
- ^ a b Adee, Sally (31 May 2017). "Human tests suggest young blood cuts cancer and Alzheimer's risk". New Scientist. Retrieved 5 May 2018.
- ^ a b Maxmen, Amy (13 January 2017). "Questionable "Young Blood" Transfusions Offered in U.S. as Anti-Aging Remedy". MIT Technology Review. Retrieved 6 May 2018.
- ^ Bercovici, Jeff. "Peter Thiel Is Very, Very Interested In Young People's Blood". Inc. Retrieved 5 May 2018.
- ^ Qualey, Erin (2017). "Yes, the blood boy on Silicon Valley is actually a thing". Hidden Remote. Retrieved 5 May 2018.
- ^ Makin, Simon (21 April 2017). "Fountain of Youth? Young Blood Infusions "Rejuvenate" Old Mice". Scientific American. Retrieved 5 May 2018.
- ^ "Can young blood really rejuvenate the old?". The Economist. 21 July 2017. Retrieved 6 May 2018.
- ^ "The vampire molecule: scientists discover why young blood helps reverse aging". CBC Radio. 3 March 2018. Retrieved 6 May 2018.